The Pyridostigmine Bromide Tablets, cataloged under National Stock Number 6505-01-725-2767, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Amneal Pharmaceuticals of New York, Llc. Government technical data includes 4 specifications, cited from the U.S. Government catalog. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 2 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-725-2767 |
| Primary Part Number | NDC60846-0559-10 |
| Item Name | Pyridostigmine Bromide Tablets |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Amneal Pharmaceuticals of New York, Llc |
| Status | ACTIVE |
| Long Action Method | EXTENDED RELEASE |
| Administration | ORAL |
| Active Medicament Medicinal Strength | 105.0 MILLIGRAMS PYRIDOSTIGMINE BROMIDE ACTIVE INGREDIENT |
| Total Primary Container Quantity | 70 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| NDC60846-0559-10 PRIMARY | Amneal Pharmaceuticals of New York, Llc (USA) |
| Reference | Meaning |
|---|---|
| 6505NCM241134 | 5/1 Secondary reference Defense Medical Standardization Board |
| 1678145 | 5/1 Secondary reference U.S. Government activity |
NSN 6505-01-725-2767 is a Pyridostigmine Bromide Tablets, manufactured by Amneal Pharmaceuticals of New York, Llc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-725-2767 has 1 manufacturer part number on file: NDC60846-0559-10 (Amneal Pharmaceuticals of New York, Llc).
Key specifications for NDC60846-0559-10: Long Action Method: EXTENDED RELEASE; Administration: ORAL; Special Features: FOR MILITARY MEDICAL USE ONLY; INDICATED FOR PRE-TREATMENT AGAINST THE LETHAL EFFECTS OF SOMAN NERVE AGENT POISONING IN ADULTS; USE IN CONJUNCTION WITH PROTECTIVE GARMENTS, INCLUDING A MASK; STORE AT 20 C TO 25 C (68 F TO 77 F); EXCURSIONS PERMITTED BETWEEN 15 C TO 30 C (59 F TO 86 F) (SEE USP CONTROLLED ROOM TEMPERATURE), OR STORE REFRIGERATED BETWEEN 2 C AND 8 C (36 F TO 46 F). PROTECT FROM HEAT AND MOISTURE. DISCARD CONTENTS OF BLISTER PACK 3 MONTHS AFTER THE MYLAR BAG IS OPENED; EACH EXTENDED-RELEASE TABLETS CONTAIN 105 MG OF PYRIDOSTIGMINE BROMIDE (EQUIVALENT TO 72.87 MG OF PYRIDOSTIGMINE BASE) FOR ORAL ADMINISTRATION; BAG OF 10 BLISTER PACK, EACH BLISTER PACK CONTAINS 7 TABLETS.; Part Name Assigned by Controlling Agency: PYRIDOSTIGMINE BROMIDE EXTENDED-RELEASE TABLETS, 105MG, 70S. 4 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.